-
公开(公告)号:US08598185B2
公开(公告)日:2013-12-03
申请号:US11453122
申请日:2006-06-13
申请人: Terrence C. Dahl , Munir A. Hussain , Robert A. Lipper , Robert L. Jerzewski , Mark M. Menning , Reza Oliyai , Taiyin Yang
发明人: Terrence C. Dahl , Munir A. Hussain , Robert A. Lipper , Robert L. Jerzewski , Mark M. Menning , Reza Oliyai , Taiyin Yang
IPC分类号: A61K31/551 , A61K31/522 , A61K31/513
CPC分类号: A61K31/683 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K31/513 , A61K31/522 , A61K31/535 , A61K31/536 , A61K31/551 , A61K31/675
摘要: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
-
公开(公告)号:US20090143314A1
公开(公告)日:2009-06-04
申请号:US12195161
申请日:2008-08-20
申请人: Terrence C. Dahl , Mark M. Menning , Reza Oliyai
发明人: Terrence C. Dahl , Mark M. Menning , Reza Oliyai
IPC分类号: A61K38/05 , A61K31/675 , A61P31/18
CPC分类号: A61K31/675 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/513 , A61K31/683 , A61K31/7076 , A61K45/06 , A61K2300/00
摘要: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
摘要翻译: 本发明涉及[2-(6-氨基 - 嘌呤-9-基)-1-甲基 - 乙氧基甲基] - 膦酸二异丙氧基羰氧基甲酯(富马酸替诺福韦地索普洛尔,Viread)和(2R,5S, 顺式)-4-氨基-5-氟-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基) - (1H) - 嘧啶-2-酮(恩曲他滨,Emtriva TM,( - ) - 顺式FTC)及其生理功能衍生物。 这些组合可用于治疗HIV感染,包括具有对核苷和/或非核苷抑制剂的抗性的HIV突变体的感染。 本发明还涉及替诺福韦地索普西富马酸和恩曲他滨的组合的药物组合物和制剂及其生理功能衍生物,以及这些组合物和制剂的使用的治疗方法。
-
公开(公告)号:US08716264B2
公开(公告)日:2014-05-06
申请号:US12204174
申请日:2008-09-04
申请人: Terrence C. Dahl , Mark M. Menning , Reza Oliyai
发明人: Terrence C. Dahl , Mark M. Menning , Reza Oliyai
IPC分类号: A61K31/675
CPC分类号: A61K31/675 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/513 , A61K31/683 , A61K31/7076 , A61K45/06 , A61K2300/00
摘要: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
摘要翻译: 本发明涉及[2-(6-氨基 - 嘌呤-9-基)-1-甲基 - 乙氧基甲基] - 膦酸二异丙氧基羰基氧基甲酯(富马酸替诺福韦地索普洛尔,Viread)和(2R,5S,顺式) -4-氨基-5-氟-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基) - (1H) - 嘧啶-2-酮(恩曲他滨,Emtriva TM,( - ) - 顺式FTC)和 其生理功能衍生物。 这些组合可用于治疗HIV感染,包括具有对核苷和/或非核苷抑制剂的抗性的HIV突变体的感染。 本发明还涉及替诺福韦地索普西富马酸和恩曲他滨的组合的药物组合物和制剂及其生理功能衍生物,以及这些组合物和制剂的使用的治疗方法。
-
公开(公告)号:US08592397B2
公开(公告)日:2013-11-26
申请号:US12195161
申请日:2008-08-20
申请人: Terrence C. Dahl , Mark M. Menning , Reza Oliyai
发明人: Terrence C. Dahl , Mark M. Menning , Reza Oliyai
IPC分类号: A61K31/675
CPC分类号: A61K31/675 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/513 , A61K31/683 , A61K31/7076 , A61K45/06 , A61K2300/00
摘要: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one(emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
摘要翻译: 本发明涉及[2-(6-氨基 - 嘌呤-9-基)-1-甲基 - 乙氧基甲基] - 膦酸二异丙氧基羰基氧基甲酯(富马酸替诺福韦地索普洛尔,Viread)和(2R,5S,顺式) -4-氨基-5-氟-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基) - (1H) - 嘧啶-2-酮(恩曲他滨,Emtriva TM,( - ) - 顺式FTC )及其生理功能衍生物。 这些组合可用于治疗HIV感染,包括具有对核苷和/或非核苷抑制剂的抗性的HIV突变体的感染。 本发明还涉及替诺福韦地索普西富马酸和恩曲他滨的组合的药物组合物和制剂及其生理功能衍生物,以及这些组合物和制剂的使用的治疗方法。
-
公开(公告)号:US20090036408A1
公开(公告)日:2009-02-05
申请号:US12204174
申请日:2008-09-04
申请人: Terrence C. Dahl , Mark M. Menning , Reza Oliyai
发明人: Terrence C. Dahl , Mark M. Menning , Reza Oliyai
IPC分类号: A61K31/506 , A61K31/675 , A61P31/12
CPC分类号: A61K31/675 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/513 , A61K31/683 , A61K31/7076 , A61K45/06 , A61K2300/00
摘要: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
摘要翻译: 本发明涉及[2-(6-氨基 - 嘌呤-9-基)-1-甲基 - 乙氧基甲基] - 膦酸二异丙氧羰基氧基甲酯(富马酸替诺福韦地索普洛尔,Viread)和(2R,5S, 顺式)-4-氨基-5-氟-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基) - (1H) - 嘧啶-2-酮(恩曲他滨,Emtriva TM,( - ) - 顺式FTC)及其生理功能衍生物。 这些组合可用于治疗HIV感染,包括具有对核苷和/或非核苷抑制剂的抗性的HIV突变体的感染。 本发明还涉及替诺福韦地索普西富马酸和恩曲他滨的组合的药物组合物和制剂及其生理功能衍生物,以及这些组合物和制剂的使用的治疗方法。
-
公开(公告)号:US08569487B2
公开(公告)日:2013-10-29
申请号:US12303207
申请日:2007-07-06
申请人: Steven S. Bondy , Terrence C. Dahl , David A. Oare , Reza Oliyai , Winston C. Tse , Vahid Zia
发明人: Steven S. Bondy , Terrence C. Dahl , David A. Oare , Reza Oliyai , Winston C. Tse , Vahid Zia
IPC分类号: C07D237/08
CPC分类号: C07D403/14
摘要: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided.
摘要翻译: 提供式(1)化合物及其盐和溶剂合物用于治疗或预防丙型肝炎病毒感染。 提供制备和配制化合物(1)的方法。
-
公开(公告)号:US20080199427A1
公开(公告)日:2008-08-21
申请号:US11825598
申请日:2007-07-06
申请人: Steven S. Bondy , Terrence C. Dahl , David A. Oare , Reza Oliyai , Winston C. Tse , Vahid Zia
发明人: Steven S. Bondy , Terrence C. Dahl , David A. Oare , Reza Oliyai , Winston C. Tse , Vahid Zia
IPC分类号: A61K31/501 , C07D471/04 , A61K38/21 , C07D237/08
CPC分类号: C07D403/14
摘要: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating compound (1) are provided.
摘要翻译: 提供式(1)化合物及其盐和溶剂合物用于治疗或预防丙型肝炎病毒感染提供制备和配制化合物(1)的方法。
-
公开(公告)号:US20100063059A1
公开(公告)日:2010-03-11
申请号:US12303207
申请日:2007-07-06
申请人: Steven S. Bondy , Terrence C. Dahl , David A. Oare , Reza Oliyai , Winston C. Tse , Vahid Zia
发明人: Steven S. Bondy , Terrence C. Dahl , David A. Oare , Reza Oliyai , Winston C. Tse , Vahid Zia
IPC分类号: A61K31/501 , C07D401/14 , A61P31/14 , A61P31/12
CPC分类号: C07D403/14
摘要: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided.
摘要翻译: 提供式(1)化合物及其盐和溶剂合物用于治疗或预防丙型肝炎病毒感染。 提供制备和配制化合物(1)的方法。
-
公开(公告)号:US07754720B2
公开(公告)日:2010-07-13
申请号:US11825598
申请日:2007-07-06
申请人: Steven S. Bondy , Terrence C. Dahl , David A. Oare , Reza Oliyai , Winston C. Tse , Vahid Zia
发明人: Steven S. Bondy , Terrence C. Dahl , David A. Oare , Reza Oliyai , Winston C. Tse , Vahid Zia
IPC分类号: C07D401/14 , A61K31/501 , A61P1/16
CPC分类号: C07D403/14
摘要: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating compound (1) are provided.
摘要翻译: 提供式(1)化合物及其盐和溶剂合物用于治疗或预防丙型肝炎病毒感染提供制备和配制化合物(1)的方法。
-
公开(公告)号:US09283182B2
公开(公告)日:2016-03-15
申请号:US12890337
申请日:2010-09-24
申请人: Terrence C. Dahl
发明人: Terrence C. Dahl
IPC分类号: A61F6/06 , A61F6/14 , A61K31/675 , A61K9/02 , A61K9/00 , A61K31/505 , A61F6/04
CPC分类号: A61K9/02 , A61F6/04 , A61K9/0014 , A61K9/0034 , A61K31/505 , A61K31/675
摘要: The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.
-
-
-
-
-
-
-
-
-